Navigation Links
Strategy developed to improve delivery of medicines to the brain
Date:9/7/2012

New research offers a possible strategy for treating central nervous system diseases, such as brain and spinal cord injury, brain cancer, epilepsy, and neurological complications of HIV. The experimental treatment method allows small therapeutic agents to safely cross the blood-brain barrier in laboratory rats by turning off P-glycoprotein, one of the main gatekeepers preventing medicinal drugs from reaching their intended targets in the brain.

The findings appeared online Sept. 4 in the Proceedings of the National Academy of Sciences, and is the result of a study from scientists at the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health.

"Many promising drugs fail because they cannot cross the blood-brain barrier sufficiently to provide a therapeutic dose to the brain," said David Miller, Ph.D., head of the Laboratory of Toxicology and Pharmacology at NIEHS, and leader of the team that performed the study. "We hope our new strategy will have a positive impact on people with brain disorders in the future."

In a two-pronged approach, the research team first determined that treating rat brain capillaries with the multiple sclerosis drug marketed as Gilenya (fingolimod) stimulated a specific biochemical signaling pathway in the blood-brain barrier that rapidly and reversibly turned off P-glycoprotein. Team members then pretreated rats with fingolimod, and administered three other drugs that P-glycoprotein usually transports away from the brain. They observed a dramatic decline in P-glycoprotein transport activity, which led to a threefold to fivefold increase in brain uptake for each of the three drugs.

Ronald Cannon, Ph.D., is a staff scientist in the Miller lab and first author on the paper. He said one of the burning questions the team wants to tackle next is to understand how the signaling system turns off P-glycoprotein. He equates the mechanism to what happens when a person flips a light switch.

"If you physically turn off a light using the button on the wall, the light will go out because the electrical current to the light bulb has been interrupted," Cannon explained. "But what happens when the signaling pathway shuts down P-glycoprotein? Does it bring in another protein to bind to the pump, take away its energy source, modify the structure of the pump, or something else?"

Cannon said the paper's findings open a new way of thinking regarding targets for drug design, a thought that is emotionally gratifying for him and many other researchers whose scientific discoveries generally don't directly translate into helping people with illnesses.

"Although much more research needs to be done, delivering therapeutics to the central nervous system is one of the final frontiers of pharmacotherapy, Cannon added."


'/>"/>

Contact: Robin Arnette
arnetter@niehs.nih.gov
919-541-5143
NIH/National Institute of Environmental Health Sciences
Source:Eurekalert

Related medicine news :

1. Scientists devise new strategy to destroy multiple myeloma
2. Strategy May Help ER Docs Spot Heart Attacks Within an Hour
3. Scientists develop new strategy to overcome drug-resistant childhood cancer
4. Cell differentiation as a novel strategy for the treatment of an aggressive type of skin cancer
5. New gene transfer strategy shows promise for limb girdle and other muscular dystrophies
6. UT Southwestern study shows treating diabetes early, intensively is best strategy
7. VisionWare and Serco Partner to Enable ‘Digital by Default’ Strategy
8. New drug strategy attacks resistant leukemia and lymphoma
9. Strategy discovered to activate genes that suppress tumors and inhibit cancer
10. Discovery suggests new combination therapy strategy for basal-like breast cancers
11. White House Drug Policy Shifts Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... WA (PRWEB) , ... May 05, 2016 , ... ... user experience, adapted to people’s every day living patterns, Amerec, a Seattle-based steam ... computer and smart phone app. , The user interface of the app, developed ...
(Date:5/5/2016)... ... 05, 2016 , ... Talent Tech Labs (TTL) is pleased to ... National Nurses Week (May 6-12). Currently, HireNurses is a job listing and ... the Talent Tech Lab Virtual Incubation program, they will dramatically expand the functionality and ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, ... can weaken the immune system and increase inflammation, both of which raise the risk ... adult congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can ...
(Date:5/5/2016)... ... 2016 , ... T.E.N., a technology and information security executive ... the 2016 ISE® Central Executive Forum and Awards Gala at the Sheraton Downtown ... of HMS, was selected as the Information Security Executive® of the Year Award ...
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind a bit of prickly ... may want to consider a treatment that some have called the next great tool ... , Microneedling, also known as skin needling, is a procedure using a device covered ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... TOWN, Grand Cayman , May 5, 2016 ... successful trial of Oxitec , s ... reduced Aedes aegypti by 96 ... Unit (MRCU) announced a new plan to fight wild Aedes aegypti, ... of these diseases on the island of Grand Cayman . ...
(Date:5/5/2016)... Research and Markets has announced the addition of the  "Market ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Emission Tomography (PET) scanner and cyclotron install base in the ... France , Germany , ... United Kingdom . Along with the current ...
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Thalassaemia Market and ... their offering.       (Logo: ... Europe Thalassaemia Market and Competitive Landscape Highlights ... pipeline products, Thalassaemia epidemiology, Thalassaemia market valuations ...
Breaking Medicine Technology: